Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MPO | P05164 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 4/20 | 0.49 |
| ▸ | SRC | P12931 | 2/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.49 |
| ▸ | ALPI | P09923 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | XIAP | P98170 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7688917 | 1.00 | KDM4E (0.54) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL8653746 | 1.00 | KDM4E (0.54) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL31599467 | 1.00 | KDM4E (0.54) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL497627 | 0.84 | KDM4E (0.55) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL2263891 | 0.84 | KDM4E (0.55) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL471925 | 0.84 | KDM4E (0.55) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL7694812 | 0.84 | KDM4E (0.55) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL6295317 | 0.84 | KDM4E (0.55) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL29415605 | 0.84 | KDM4E (0.55) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL12838301 | 0.83 | KDM4E (0.51) | KDM4EMAPTMEN1LMNAMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108026162-A | Cystine knot scaffold platform | 豪夫迈·罗氏有限公司 | 2018-05-11 | — | — | CN | claimed |
| WO-2025111511-A2 | REVERSIBLY REACTIVE AFFINITY SELECTION MASS SPECTROMETRY AND USES THEREOF | CALICO LIFE SCIENCES LLC (US) | 2025-05-30 | — | — | WO | disclosed |
| US-20250057861-A1 | HALOGENATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | Enveric Biosciences Canada Inc. (CA) | 2025-02-20 | — | — | US | disclosed |
| US-20240417764-A1 | METHODS FOR THE PRODUCTION OF TRYPTOPHANS, TRYPTAMINES, INTERMEDIATES, SIDE PRODUCTS AND DERIVATIVES | MIAMI UNIVERSITY | 2024-12-19 | — | — | US | disclosed |
| US-12138276-B2 | Halogenated psilocybin derivatives and methods of using | Enveric Biosciences Canada Inc. (CA) | 2024-11-12 | — | — | US | disclosed |
| US-20240299427-A1 | HALOGENATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | Enveric Biosciences Canada Inc. (CA) | 2024-09-12 | — | — | US | disclosed |
| EP-4426676-A2 | METHODS FOR THE PRODUCTION OF TRYPTOPHANS, TRYPTAMINES, INTERMEDIATES, SIDE PRODUCTS AND DERIVATIVES | MIAMI UNIVERSITY (US) | 2024-09-11 | — | — | EP | disclosed |
| US-11998557-B2 | Halogenated psilocybin derivatives and methods of using | Enveric Biosciences Canada Inc. (CA) | 2024-06-04 | — | — | US | disclosed |
| WO-2023081837-A9 | METHODS FOR THE PRODUCTION OF TRYPTOPHANS, TRYPTAMINES, INTERMEDIATES, SIDE PRODUCTS AND DERIVATIVES | MIAMI UNIVERSITY (US) | 2024-03-14 | — | — | WO | disclosed |
| US-20230293558-A1 | HALOGENATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | MAGICMED INDUSTRIES INC. (CA) | 2023-09-21 | — | — | US | disclosed |
| WO-2023081837-A2 | METHODS FOR THE PRODUCTION OF TRYPTOPHANS, TRYPTAMINES, INTERMEDIATES, SIDE PRODUCTS AND DERIVATIVES | MIAMI UNIVERSITY (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2022047579-A1 | HALOGENATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | MAGICMED INDUSTRIES INC. (CA) | 2022-03-10 | — | — | WO | disclosed |
| WO-2007002594-A1 | COSMETIC COMPOSITIONS AND METHODS USING TRANSFORMING GROWTH FACTOR-BETA MIMICS | BHATNAGAR RAJENDRA S (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002469-A2 | THERAPEUTIC COMPOSITIONS AND METHODS USING TRANSFORMING GROWTH FACTOR-BETA MIMICS | BHATNAGAR RAJENDRA S (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060293227-A1 | Cosmetic compositions and methods using transforming growth factor-beta mimics | BHATNAGAR RAJENDRA S | 2006-12-28 | — | — | US | disclosed |
| US-20060293228-A1 | Therapeutic compositions and methods using transforming growth factor-beta mimics | BHATNAGAR RAJENDRA S | 2006-12-28 | — | — | US | disclosed |
| US-6774212-B2 | FOR THERAPY OF VIRAL INFECTION OR AS AN ASSAY STANDARD OR REAGENT | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-08-10 | — | — | US | disclosed |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-05 | — | — | US | disclosed |
| EP-0707490-A1 | NEUROPEPTIDE Y ANTAGONISTS AND AGONISTS | UNIVERSITY OF CINCINNATI (US) | 1996-04-24 | — | — | EP | disclosed |
| WO-1995000161-A1 | NEUROPEPTIDE Y ANTAGONISTS AND AGONISTS | UNIVERSITY OF CINCINNATI (US) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12138276-B2 | Halogenated psilocybin derivatives and methods of using | CES2, MAOB, CNR1 | KDM4E 3792/4885MAPT 3922/4885MEN1 3615/4885 |
| US-20240299427-A1 | HALOGENATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | CES2, MAOB, CNR1 | KDM4E 3792/4885MAPT 3922/4885MEN1 3615/4885 |
| US-20230293558-A1 | HALOGENATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | CES2, MAOB, CNR1 | KDM4E 3792/4885MAPT 3922/4885MEN1 3615/4885 |
| US-11998557-B2 | Halogenated psilocybin derivatives and methods of using | CES2, MAOB, CNR1 | KDM4E 3792/4885MAPT 3922/4885MEN1 3615/4885 |
| US-20250057861-A1 | HALOGENATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | CES2, MAOB, CNR1 | KDM4E 3792/4885MAPT 3922/4885MEN1 3615/4885 |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | CES1, CYP51A1, SPINT2 | KDM4E 643/4885MAPT 3370/4885MEN1 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.